[
    [
        {
            "time": "",
            "original_text": "高瓴年内调研16家公司，刚刚入手广联达，接下来会买谁？",
            "features": {
                "keywords": [
                    "高瓴",
                    "调研",
                    "广联达"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "建筑信息化"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "高瓴年内调研16家公司，刚刚入手广联达，刚刚入手广联达，接下来会买谁？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业半年度策略报告：紧抓“抗疫”和“自主定价”两大主线",
            "features": {
                "keywords": [
                    "医药",
                    "抗疫",
                    "自主定价",
                    "策略报告"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业半年度策略报告：紧抓“抗疫”和“自主定价”两大主线",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "两大实控人身家超王健林，揭开医药股暴涨的面纱",
            "features": {
                "keywords": [
                    "医药股",
                    "暴涨",
                    "实控人"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "两大实控人身家超王健林，揭开医药股暴涨的面纱",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 10,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会，重点关注医药新基建和医药大消费",
            "features": {
                "keywords": [
                    "医药生物",
                    "疫情后周期",
                    "医药新基建",
                    "医药大消费"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会，重点关注医药新基建和医药大消费",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
            "features": {
                "keywords": [
                    "医药",
                    "高景气赛道",
                    "龙头战略"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]